Do you want to read an article? Please log in or register.
Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer
Sci Rep
Sa-Nguansai S, Rattanasiri S, Pornsuriyasak P, Numthavaj P, McKay GJ, Attia J, Thakkinstian A
doi: 10.1038/s41598-025-05823-2
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Zeng Z, Feng S, Gao T, Chen C, Chen J, Chen J, Lian Y
doi: 10.1016/j.cllc.2025.04.010
Lung Cancer
Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis
Clin Lung Cancer
Choucair K, Jang H, Jalal SI, Hadid T, Uprety D, Kim S, Mamdani H
doi: 10.1016/j.cllc.2025.10.014
Lung Cancer
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer
Lung Cancer
Desai RK, Zhou EJ, Chan KKW
doi: 10.1016/j.lungcan.2025.108812
Lung Cancer
MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review
Lung Cancer
Shi Y, Chen R, Xiong Y, Geng R, Guo C, Liu L, Chen Y, Wang Y
doi: 10.1016/j.lungcan.2025.108634
Lung Cancer
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Semin Oncol
Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A
doi: 10.1016/j.seminoncol.2025.152431
RECOMMENDED
Lung Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015